Zimmer Biomet reports Q2 earnings beat despite stock volatility

Zimmer Biomet reported second-quarter 2026 results that exceeded analyst expectations, posting an adjusted earnings per share (EPS) of $2.07 against a consensus estimate of $2.01. The medical technology company recorded revenue of $2.18 billion and a net profit of $198.3 million, representing a profitability margin of 9.11%.

Despite the earnings beat, the company's stock experienced volatility. On September 23, 2026, the share price fell 4.09% to $90.14 on the NYSE. However, other reports indicate the stock has traded around $95.36, remaining below the average analyst price target of $107.57.

Management is currently focusing on margin improvement through 'Project Optima' to enhance cost structures. The company is also shifting its revenue mix toward higher-value technology platforms, such as robotics-assisted systems, to support sustainable margins.